Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
Randomized, multicenter, open-label, Phase 3 registration study designed to evaluate the
safety and efficacy of milademetan compared to trabectedin in patients with unresectable
(i.e., where resection is deemed to cause unacceptable morbidity or mortality) or metastatic
DD liposarcoma that progressed on 1 or more prior systemic therapies, including at least 1
anthracycline-based therapy.